+90 (212) 414 20 00 | didem.tastekin@istanbul.edu.tr
Ana Sayfa / Yayınlar

Bilimsel Yayınlar

Uluslararası tıp literatürüne katkı sağlayan makaleler, araştırmalar ve kitap bölümleri arşivi.

106+ Uluslararası Yayın
650+ Bilimsel Atıf
16 H-İndeks
2026

Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma

Harbi E., Byrne Y. Y., BOZBEY H. U., TAŞTEKİN D., Oncul O., Hosseiny S., Yahya D., Yildiz O., Erdoğan M., Slocum A. K., et al.

Apoptosis, cilt.31, sa.2, 2026 (SCI-Expanded, Scopus)

2026

Evaluating Comorbidity Scores in Geriatric Ovarian Cancer: A Retrospective Cohort Analysis

ÇOKGEZER S., AK N., Senkal M., Safaraliyeva A., TAŞTEKİN D., SAİP P. M.

Medicina (Lithuania), cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

2025

IGF Pathway Components as Potential Biomarkers in Gastric Cancer

CEYLANER B., ŞAHİN F., YILDIZ A., TAŞTEKİN D., GÖK A. F. K., BAYKAL A. T.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, cilt.26, sa.22, 2025 (SCI-Expanded, Scopus)

2025

A Pilot Study of Exploring miRNA-Protein Interaction Networks in Pancreatic Ductal Adenocarcinoma Patients: Implications for Diagnosis and Prognosis

Şen S., Özgel M. Ç., Tunçer Ş. B., Bozbey H. U., Karabulut S., Taştekin D.

DIAGNOSTICS, cilt.15, sa.19, 2025 (SCI-Expanded, Scopus)

2025

Enhancing Antitumor Efficacy of MUC1 mRNA Nano-Vaccine by CTLA-4 siRNA-Mediated Immune Checkpoint Modulation in Triple Negative Breast Cancer Mice Model

Monfaredan A., Şen S., Fathi N. K., Taştekin D., Hosseininasab A., Bozbey H. U., Öncül O.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, cilt.26, sa.17, 2025 (SCI-Expanded, Scopus)

2025

Exosome Enveloped by Nano Lipid Particle a New Model for Signal Transducer and Activator of Transcription 3 Silencer Ribonucleic Acid Delivery System to a Glioblastoma Mice Model

Monfaredan A., ŞEN S., Hosseininasab A., TAŞTEKİN D., Fazli G., Bozbey H. U., Yousefi N., Hocaoğlu M., Öncül M. O., Özen R. S.

CANCERS, cilt.17, sa.10, 2025 (SCI-Expanded, Scopus)

2024

Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study

Demirci NS, Azizy A, Paksoy N, Dogan I, Karabulut S, Karahan L, Tastekin D.

Medicine (Baltimore). 2024 Mar 1;103(9):e37259. doi: 10.1097/MD.00000000000037259. PMID: 38428877.

2024

Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer

Karabulut S, Sen S, Soydinç HO, Dogan I, Taştekin D, Karabulut M, Duman M, Turan M.

Pathol Res Pract. 2024 Feb;254:155094. doi: 10.1016/j.prp.2024.155094. PMID: 38219497.

2024

Disease characteristics and prognostic factors of colorectal cancer patients with bone metastasis: A real-world data from Turkey

Karabulut S, Afsar CU, Khanmammadov N, Karahan L, Paksoy N, Dogan I, Ferhatoglu F, Tastekin D.

J Cancer Res Ther. 2024 Jan 22. doi: 10.4103/jcrt.jcrt_392_23. PMID: 38261430.

2024

Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?

Karabulut S, Afsar CU, Paksoy N, Ferhatoglu F, Dogan I, Tastekin D.

J Cancer Res Ther. 2024 Jan 22. doi: 10.4103/jcrt.jcrt_469_23. PMID: 38261434.

2024

The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündoğdu A, Sever N, Ayhan M, Çelebi A, Majidova N, et al.

J Chemother. 2024 Jan 23:1-9. doi: 10.1080/1120009X.2024.2305066. PMID: 38263804.

2023

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, et al.

Oncologist. 2023 Oct 3;28(10):875-884. PMID: 37402517.

2023

Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience

Tastekin D, Paksoy N, Dogan I, Ferhatoglu F, Khanmammadov N, Bozhey HU, Karabulut S.

J Cancer Res Ther. 2023 Jan-Mar;19(2):253-258. doi: 10.4103/jcrt.jcrt_672_22. PMID: 37006064.

2023

Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer

Dogan I, Gurbuz M, Aydin E, Karabulut S, Tastekin D, Utkan G.

J Cancer Res Ther. 2023 Jan 1;19(Suppl 2):S747-S751. doi: 10.4103/jcrt.jcrt_1520_22. PMID: 38384050.

2023

Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

Senyurek S, Saglam S, Saglam EK, Yanar H, Gok K, Tastekin D, Akbas CK, Sakin ND, Kartal GD, Balik E, Keskin M, Sanli Y, Gulluoglu M, Akgun Z.

Oncol Res. 2023 Jul 21;31(5):689-696. doi: 10.32604/or.2023.030351. PMID: 37547762.

2022

Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Erol C, Sendur Mehmet AN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, et al.

J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. PMID: 36510987.

2022

FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Ay S, Atci MM, Arikan R, Dülgar Ö, Özyükseler DT, Paksoy N, Doğan İ, Öztosun B, Taştekin D, Öven BB, Gümüş M.

J Chemother. 2022 Nov;34(7):465-471. doi: 10.1080/1120009X.2022.2026125. PMID: 35037592.

2022

Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors

Dogan I, Tastekin D, Karabulut S, Sakar B.

J Dig Dis. 2022 Aug;23(8-9):493-499. doi: 10.1111/1751-2980.13123. PMID: 36081250.

2022

Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer

Dogan I, Karabulut S, Tastekin D, Ferhatoglu F, Paksoy N, Sakar B.

J Coll Physicians Surg Pak. 2022 Aug;32(8):1014-1019. doi: 10.29271/jcpsp.2022.08.1014. PMID: 35932125.

2022

Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey

Karabulut S, Dogan I, Usul Afsar C, Karabulut M, Ak N, Duran A, Tastekin D.

J Oncol Pharm Pract. 2022 Jan;28(1):127-134. doi: 10.1177/1078155220987291. PMID: 33435820.

2022

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.37, sa.4, ss.478-483, 2022 (ESCI, Scopus, TRDizin)

2022

Quantification of cell-free circulating mitochondrial DNA copy number variation in hepatocellular carcinoma

Yalcinkaya B., Tastekin D., Guezelbulut F., Akgoz M., PENÇE S.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, cilt.68, sa.9, ss.1161-1165, 2022 (SCI-Expanded, Scopus)

2022

Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers

Karabulut S., Topalgokceli M. S., Tastekin D.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.6, sa.1, ss.12-15, 2022 (ESCI, TRDizin)

2021

Does nutritional status affect treatment tolerability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study

Karabulut S, Dogan I, Usul Afsar C, Karabulut M, Karaman S, Ferhatoglu F, Tastekin D.

J Oncol Pharm Pract. 2021 Sep;27(6):1357-1363. doi: 10.1177/1078155220959427. PMID: 32957862.

2021

WHAT'S NEW IN METASTATIC COLON CANCER TREATMENT?

Karabulut S., Karabulut M., Tastekin D.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE, cilt.84, sa.3, ss.425-429, 2021 (ESCI, TRDizin)

2021

Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors

Dogan I., Tastekin D., Karabulut S., Sakar B.

JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021 (SCI-Expanded, Scopus)

2021

Role of mir-33a, mir-203b, mir361-3p, and mir-424 in hepatocellular carcinoma

Yalçınkaya B, Güzel E, Taştekin D, Pençe S.

Turk J Med Sci. 2021 Apr 30;51(2):638-643. doi: 10.3906/sag-2004-214. PMID: 33098283.

2020

Efficacy of regorafenib in the second- and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Sahin AB, et al.

J BUON. 2020 Jul-Aug;25(4):1897-1903. PMID: 33099930.

2020

A retrospective evaluation of geriatric patients with gastric cancer receiving systemic chemotherapy

Tatli AM, Urakci Z, Tastekin D, Koca D, Goksu SS, Uyeturk U, Kaplan MA, Coskun HS.

J Cancer Res Ther. 2020 Dec;16(Supplement):S138-S143. doi: 10.4103/jcrt.JCRT_563_18. PMID: 33380668.

2020

Examination of the expression levels of MACC1, Filamin A and FBXW7 genes in colorectal cancer patients

Yesilkaya F., Tastekin D., Al Saadoni H., Ergen A., Pence S.

NORTHERN CLINICS OF ISTANBUL, cilt.7, sa.1, ss.1-5, 2020 (ESCI, TRDizin)

2019

Investigation of JAM-A (rs790056) and LFA-1 (rs8058823) gene variants in Turkish colorectal cancer patients

Çaykara B, Alsaadoni H, Pençe HH, Pençe S, Yilmaz Aydogan H, Taştekin D.

Turk J Gastroenterol. 2019 Oct;30(10):872-876. doi: 10.5152/tjg.2019.19141. PMID: 31625931.

2019

The Association of Pancreatic Cancer and PALB2 Gene Mutations in the Turkish Population

Turkcan G. K., Odemis D., Avsar M., Tuncer S. B., Erciyas S., Erdogan O., Tastekin D., Karabulut S., Kaytan E., Yazici H.

TURK ONKOLOJİ DERGİSİ- TURKISH JOURNAL OF ONCOLOGY, cilt.34, sa.4, ss.283-290, 2019 (ESCI, Scopus, TRDizin)

2019

ROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) IN THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA AND MONITORING TREATMENT RESPONSE

Bademler S., Ucuncu W. Z., Sari M., Yasasever C., Afsar C. U., Tastekin D.

ACTA MEDICA MEDITERRANEA, cilt.35, sa.1, ss.71-75, 2019 (SCI-Expanded, Scopus)

2018

Evaluation of JAM-A (rs790056) and LFA-1 (rs8058823) Variants in Colorectal Cancer

Caykara B., Alsaadoni H., PENCE H. H., Pence S., Aydogan H., Tastekin D.

ACTA PHYSIOLOGICA, cilt.225, ss.25, 2018 (SCI-Expanded, Scopus)

2018

Neoadjuvant volumetric modulated arc therapy in rectal cancer and the correlation of pathological response with diffusion-weighted MRI and apoptotic markers

Gurdal N, Fayda M, Alishev N, Bakir B, Tastekin D, Aykan F, Gezer U, Balik E, Saglam EK, Oral EN, et al.

Tumori. 2018 Aug;104(4):266-272. doi: 10.5301/tj.5000702. PMID: 29218690.

2018

Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)

Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, Inanc M, Elkiran ET, Gunaydin Y, Menekse S, Topcu TO, et al.

J Cancer Res Ther. 2018 Apr-Jun;14(3):578-582. doi: 10.4103/0973-1482.176417. PMID: 29893321.

2017

Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection

Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Ustaalioglu BB, Uysal M, et al.

Clin Colorectal Cancer. 2017 Sep;16(3):220-227. doi: 10.1016/j.clcc.2016.08.002. PMID: 27670893.

2016

Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO)

Aydin D., Sendur M. A., KEFELİ U., Unal O. U., TAŞTEKİN D., Akyol M., Tanrikulu E., Ciltas A., Ustailoglu B. B., ŞENER DEDE D., et al.

JOURNAL OF BUON, cilt.21, sa.5, ss.1242-1249, 2016 (SCI-Expanded, Scopus)

2016

Importance of Performing Radiotherapy and Chemotherapy in the Same Clinic and Bad Prognostic Factors for Small-cell Lung Cancer Patients

Kiziltan H. S., TAŞTEKİN D., ERİŞ A. H., Taspinar O., Ismayilova M., MAYADAĞLI A.

BEZMIALEM SCIENCE, cilt.4, sa.2, ss.51-55, 2016 (ESCI, TRDizin)

2016

Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients

Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.

Journal of gastrointestinal cancer, cilt.47, ss.182-6, 2016 (Scopus)

2016

Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer

Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.

BIOMEDICAL REPORTS, cilt.4, sa.5, ss.609-614, 2016 (ESCI, Scopus)

2016

Clinical significance of serum laminin levels in patients with lung cancer

Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.

BIOMEDICAL REPORTS, cilt.4, sa.4, ss.485-488, 2016 (ESCI, Scopus)

2016

Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients

Tas F., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICAL REPORTS, cilt.4, sa.4, ss.489-492, 2016 (ESCI, Scopus)

2016

Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyildiz D.

MOLECULAR AND CLINICAL ONCOLOGY, cilt.4, sa.4, ss.655-659, 2016 (ESCI, Scopus)

2016

Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?

Erturk K, Tastekin D, Gundogdu G, Tas F, Vatansever S.

Biomed Pharmacother. 2016 Feb;77:27-9. doi: 10.1016/j.biopha.2015.11.003. PMID: 26796262.

2016

Serum activated leukocyte cell adhesion molecule and intercellular adhesion molecule-1 in patients with gastric cancer: Can they be used as biomarkers?

Erturk K, Tastekin D, Bilgin E, Serilmez M, Bozhey HU, Sakar B.

Biomed Pharmacother. 2016 Feb;77:86-91. doi: 10.1016/j.biopha.2015.12.004. PMID: 26796269.

2016

The relationship of beck depression inventory with vitamin D levels and visceral fat mass in cancer patients

Tuna S., Mert M., Soyluk O., Okuturlar Y., Kocoglu H., Tastekin D.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, cilt.9, sa.5, ss.8719-8724, 2016 (SCI-Expanded, Scopus)

2016

Clinical significance of serum protease activated receptor1 levels in patients with lung cancer

Erturk K, Tastekin D, Bilgin E, Tas F, Disci R, Duranyildiz D.

Eur Rev Med Pharmacol Sci. 2016 Jan;20(2):243-9. PMID: 26875892.

2016

Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer

Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU, Vatansever S.

Tumour Biol. 2016 Jan;37(1):405-12. doi: 10.1007/s13277-015-3791-8. PMID: 26219895.

2015

Plasma homocysteine, folate and vitamin B12 levels in patients with lung cancer

Tastekin D, Erturk K, Bozhey HU, Olmuscelik O, Kiziltan H, Tuna S, Tas F.

Exp Oncol. 2015 Sep;37(3):218-22. PMID: 26422109.

2015

Bilateral Cystoid Macular Edema Secondary to Paclitaxel Treatment

Tezcan Y, Surmeli M, Tastekin D, Koc M.

Arch Iran Med. 2015 Sep;18(9):606-7. PMID: 26317603.

2015

Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma

Turan N, Benekli M, Unal OU, Unek IT, Tastekin D, Dane F, Algin E, Ulger S, Eren T, Topcu TO, et al.

Chin J Cancer Res. 2015 Aug;27(4):408-16. doi: 10.3978/j.issn.1000-9604.2015.07.02. PMID: 26361412.

2015

Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer

Tas F, Tilgen Yasasever C, Karabulut S, Tastekin D, Duranyildiz D.

Biomed Pharmacother. 2015 Mar;70:19-23. doi: 10.1016/j.biopha.2014.12.042. PMID: 25776475.

2015

Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer

Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerkesli A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, et al.

J BUON. 2015 Mar-Apr;20(2):573-9. PMID: 26011355.

2015

Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer

Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D.

Tumour Biol. 2015 Mar;36(3):2097-103. doi: 10.1007/s13277-014-2823-0. PMID: 25407475.

2015

Alpha-fetoprotein (AFP) elevation gastric adenocarcinoma and importance of AFP change in tumor response evaluation

Tatli AM, Urakci Z, Kalender ME, Arslan H, Tastekin D, Kaplan MA.

Asian Pac J Cancer Prev. 2015;16(5):2003-7. doi: 10.7314/apjcp.2015.16.5.2003. PMID: 25773864.

2015

Dietary and demographical risk factors for oesophageal squamous cell carcinoma in the Eastern Anatolian region of Turkey where upper gastrointestinal cancers are endemic

Koca T, Arslan D, Basaran H, Cerkesli AK, Tastekin D, Sezen D, Koca O, Binici DN, Bassorgun CI, Ozdogan M.

Asian Pac J Cancer Prev. 2015;16(5):1913-7. doi: 10.7314/apjcp.2015.16.5.1913. PMID: 25773848.

2015

Circulating annexin A2 as a biomarker in gastric cancer patients: correlation with clinical variables

Tas F, Tilgen Yasasever C, Karabulut S, Tastekin D, Duranyildiz D.

Biomed Pharmacother. 2015 Feb;69:237-41. doi: 10.1016/j.biopha.2014.11.030. PMID: 25661367.

2015

Radioprotectant and Cytotoxic Effects of Spirulina in Relapsed Verrucous Vulvar Cancer: A Case Report

Kiziltan HS, Gunes Bayir A, Taspinar O, Yucesan G, Tastekin D, Sonmez FC, Coban G, Kilic G, Eris AH, Aydin T, Akcakaya A, Mayadagli A.

Altern Ther Health Med. 2015;21 Suppl 2:68-72. PMID: 26315032.

2015

Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients

Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Eshab O, Turker I, Uysal Sonmez O, Oksuzoglu B.

J BUON. 2015 Jan-Feb;20(1):28-34. PMID: 25778294.

2015

The Effects of Topical Insulin Application on Wound Healing

Kargin S, Tastekin D, Kilic K, Cezik A, Cakir M, Kucukkartallar T, Kokbudak N.

EUROPEAN JOURNAL OF GENERAL MEDICINE, cilt.12, sa.4, ss.302-306, 2015 (ESCI, Scopus, TRDizin)

2014

The efficacy of Pistacia Terebinthus soap in the treatment of cetuximab-induced skin toxicity

Tastekin D, Tambas M, KILIC K, Erturk K, ARSLAN D.

INVESTIGATIONAL NEW DRUGS, cilt.32, sa.6, ss.1295-1300, 2014 (SCI-Expanded, Scopus)

2014

Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients

Tastekin D, Kargin S, KARABULUT M, Yaldiz N, Tambas M, Gurdal N, TATLI A. M, Arslan D, Gok A. F. K, Aykan F.

TUMOR BIOLOGY, cilt.35, sa.12, ss.11871-11877, 2014 (SCI-Expanded, Scopus)

2014

Clinical significance of serum fibronectin and vitronectin levels in melanoma patients

Tas F, Karabulut S, Bilgin E, Tastekin D, Duranylidiz D.

MELANOMA RESEARCH, cilt.24, sa.5, ss.475-479, 2014 (SCI-Expanded, Scopus)

2014

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

Tas F, Karabulut S, Bilgin E, Tastekin D, Duranylidiz D.

TUMOR BIOLOGY, cilt.35, sa.9, ss.9303-9309, 2014 (SCI-Expanded, Scopus)

2014

The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

Karabulut S., Tas F., Tastekin D., KARABULUT M., Yasasever C., Ciftci R., Guveli M., Fayda M., Vatansever S., Serilmez M., et al.

TUMOR BIOLOGY, cilt.35, sa.9, ss.8849-8860, 2014 (SCI-Expanded, Scopus)

2014

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer

TURAN N., Benekli M., DANE F., Unal O. U., Kara H. V., KOCA D., BALVAN O., EREN T., Tastekin D., HELVACI K., et al.

Thoracic cancer, cilt.5, sa.5, ss.398-404, 2014 (SCI-Expanded, Scopus)

2014

Clinical significance of serum tenascin-C levels in breast cancer

Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., Vatansever S.

TUMOR BIOLOGY, cilt.35, sa.7, ss.6619-6625, 2014 (SCI-Expanded, Scopus)

2014

Clinical significance of serum tenascin-c levels in epithelial ovarian cancer

Didem T., Faruk T., Senem K., Derya D., Murat S., Murat G., OZNUR K.

TUMOR BIOLOGY, cilt.35, sa.7, ss.6777-6782, 2014 (SCI-Expanded, Scopus)

2014

Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology

Uyeturk U., Oksuzoglu B., Akman T., Turker I., Sener N., Tastekin D., Bal O., Berk V., Arslan U. Y., Urakci Z., et al.

MEDICAL ONCOLOGY, cilt.31, sa.4, 2014 (SCI-Expanded, Scopus)

2014

Impact of Poster Presentations on Academic Knowledge Transfer from the Oncologist Perspective in Turkey

Arslan D., Koca T., Tastekin D., Basaran H., Bozuck H.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.18, ss.7707-7711, 2014 (SCI-Expanded, Scopus)

2014

Clinicopathologic Features and Molecular Subtypes of Breast Cancer in Young Women (Age <=35)

Goksu S. S., Tastekin D., Arslan D., Gunduz S., TATLI A. M., Unal D., Salim D., Guler T., COSKUN H. S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.16, ss.6665-6668, 2014 (SCI-Expanded, Scopus)

2014

Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study

KIZILTAN H. S., Bayir A. G., Tastekin D., COBAN G., Eris A. H., AYDIN T., Mayadagil A.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.15, sa.20, ss.8591-8594, 2014 (SCI-Expanded, Scopus)

2014

Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment

Mehmet K., Sener C., Uyeturk U., Seker M., Tastekin D., Tonyali O., Balakan O., Yazici O. K., Urakci Z., Isikdogan A., et al.

CONTEMPORARY ONCOLOGY, cilt.18, sa.4, ss.273-278, 2014 (ESCI, Scopus)

2013

Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY, cilt.34, sa.6, ss.3529-3536, 2013 (SCI-Expanded, Scopus)

2013

Rectal cancer in pregnancy: a case report and review of the literature

Dogan N., Tastekin D., Kerimoglu O., Pekin A., Celik C.

Journal of gastrointestinal cancer, cilt.44, ss.354-6, 2013 (SCI-Expanded, Scopus)

2013

Efficiency and Side Effects of Sorafenib Therapy for Advanced Hepatocellular Carcinoma: A Retrospective Study by the Anatolian Society of Medical Oncology

Berk V., Kaplan M. A., Tonyali O., Buyukberber S., Balakan O., ÖZKAN M., Demirci U., Ozturk T., Bilici A., Tastekin D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.14, sa.12, ss.7367-7369, 2013 (SCI-Expanded, Scopus)

2010

The biochemical effectiveness of N-acetylcysteine in experimental spinal cord injury in rats

Hanci V., Kerimoğlu A., Koca K., Başkesen A., Kiliç K., Tastekin D.

Turkish journal of trauma & emergency surgery, cilt.16, ss.15-21, 2010 (SCI-Expanded, Scopus, TRDizin)

2009

[The opinions of Turkish physicians about the tasks of tuberculosis central dispensary]

Tanrikulu A., Palanci Y., Eren D., Yilmaz G., Karaca M., Abakay A., Taştekin D.

Tuberkuloz ve toraks, cilt.57, ss.32-7, 2009 (ESCI, Scopus, TRDizin)

2008

Correlation between the erythrocyte sedimentation rate and blood nitric oxide levels in rabbits?

Uzun M., Saral S., Atakisi O., Yapar K., Uzlu E., Citił M., Tastekin D., Erdogan H. M.

2008

2008

Investigation of free radical scavenging enzyme activities and lipid peroxidation in liver tissue of zinc deficient rats

Kaya H., Taysi S., Kaya A., Boyuk A., DURSUN H., Islamoglu Y., Tastekin D., Cikman O.

Asian Journal of Chemistry, cilt.20, sa.2, ss.1068-1074, 2008 (SCI-Expanded, Scopus)

2006

Hypoglycaemic effect of Artemisia herba-alba in experimental hyperglycaemic rats

Taştekin D., ATASEVER M., Adigüzel G., Keleş M., Taştekin A.

Bulletin of the Veterinary Institute in Pulawy, cilt.50, sa.2, ss.235-238, 2006 (SCI-Expanded, Scopus)

2024

High-Dose Vitamin C Is an Unorthodox Approach to Cancer Treatment

Şen S, Ugar M., Bozbey H. U., Taştekin D.

Original Research and Reviews in the Field of Medical Oncology, Platanus Publishing, Ankara, ss.5-44, 2024

2024

The Role of Extracellular Vesicles in Drug Resistance and Treatment of Metastatic Cancers

Şen S., Taştekin D.

Original Research and Reviews in the Field of Medical Oncology, Platanus Publishing, Ankara, ss.45-72, 2024

2023

PANKREAS KANSERLİ HASTALARIN PERIFERİK KANINDA EPS8 VE KANK1 GEN EKSPRESYONLARININ İNCELENMESİ

ÖZGEL M. Ç., AKDENİZ ÖDEMİŞ D., TUNÇER Ş. B., TAŞTEKİN D., YAZICI H.

9. uluslararası beslenme obezite ve toplum sağlığı kongresi, 28 - 29 Ekim 2023, (Özet Bildiri)

2020

Trastuzumab-based treatment of HER2-positive metastatic gastric cancer

Dogan I., Karabulut S., Tastekin D., Paksoy N., Sakar B., Vatansever S.

ESMO 22nd World Congress on Gastrointestinal Cancer, 2020, cilt.31, (Özet Bildiri)

2020

The frequencies and prognostic significance of ABO blood and rhesus (D) groups in HER2-positive gastric cancer

Dogan I., Gurbuz M., Aydin E., Tastekin D., Karabulut S., Utkan G.

ESMO 22nd World Congress on Gastrointestinal Cancer, 2020, cilt.31, (Özet Bildiri)

2020

Does nutritional status affect treatment tolerability, response, and survival in metastatic colorectal cancer patients?

Karabulut S., Dogan I., Afsar C. U., Karabulut M., Karaman S., Ferhatoglu F., Tastekin D.

Gastrointestinal Cancers Symposium of ASCO, 2020, cilt.38, (Özet Bildiri)

2016

Mide Kanserinde Serum Interleukin-29, Interleukin-32 ve Tumor Necrosis Factor Alpha'nın Klinik Önemi

ERTÜRK K., TAŞTEKİN D., SERİLMEZ M., BİLGİN DOĞRU E., BOZBEY H. U., VATANSEVER S.

3. Ulusal İmmüno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, 2016, (Özet Bildiri)

2016

Radyoterapi ve Kemoterapinin Aynı Klinikte Yapılmasının Önemi

TAŞTEKİN D., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, 2016, ss.45, (Tam Metin Bildiri)

2015

Nüks meme kanserinde reoperatif sentinel lenf nodu biyopsisi: Aksilla korunabilir mi?

Karanlık H., Özgür İ., Kılıç B., Şanlı Y., Önder S., Taştekin D., Şen F.

13. Ulusal Meme Hastalıkları Kongresi, 2015, ss.1, (Özet Bildiri)

2015

The role of adhesion molecules in hepatocellular carcinoma

Tastekin D., DİKİLİTAS M., HARPUTLUOGLU H., Erturk K., CELEBI K., Sen F., BOZBEY H. U.

Annual Meeting of ASCO, 2015, cilt.33, (Özet Bildiri)

2015

The prognostic value of lymph node ratio in patients with curatively resected pancreatic adenocarcinoma

Turan N., Araz M., Algin E., Unal O. U., Benekli M., Tastekin D., Dane F., Unek T., Eren T., Turkmen E., et al.

Annual Meeting of ASCO, 2015, cilt.33, (Özet Bildiri)

2015

Serum Hepatosit Büyüme Faktörünün Akciğer Kanserli Hastalarda Tanısal Değeri

ŞEN F., BOZBEY H., ÇİFTÇİ R., KILIÇ L., YILDIZ İ., TAŞTEKİN D., et al.

21. Ulusal Kanser Kongresi, 2015, ss.1, (Tam Metin Bildiri)

2015

Hepatosellüler karsinomda galektin-3 ve fibronektin molekülleri yeni bir tümör belirteci olabilir mi?

SERİLMEZ M., AKYÜZ M., TAŞTEKİN D., OĞUZ SOYDİNÇ H., DURANYILDIZ D.

21. Ulusal Kanser Kongresi, 2015, ss.1, (Tam Metin Bildiri)

2014

Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer

CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., YILDIZ I., Keskin S., BOZBEY H. U., Kilic L., et al.

50th Annual Meeting of ASCO, 2014, cilt.32, (Özet Bildiri)

2014

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) cud vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer

KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., Tas F., Duranyildiz D., Aydiner A.

50th Annual Meeting of ASCO, 2014, cilt.32, (Özet Bildiri)

2014

Clinical significance of serum caveolin-1 levels in melanoma

Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.

50th Annual Meeting of ASCO, 2014, cilt.32, (Özet Bildiri)

2014

Metastatik rektum kanseri olgularında kısa dönem radyoterapinin katkısı

İBİŞ K., ÖZKURT S., DAĞOĞLU SAKİN R. N., KAYTAN SAĞLAM E., TAŞTEKİN D., KESKİN M., BALIK E., GÜLLÜOĞLU M., ORAL E. N., AYKAN F., et al.

11. Ulusal Radyasyon Onkolojisi Kongresi, 2014, (Özet Bildiri)

2014

Nazal Kavite Kaynaklı Tipik Karsinoid Tümör: Olgu sunumu

Gürdal N., Taştekin D., Güveli M. E., Özkaya K., Meral R., Altun M.

11. Ulusal Radyasyon Onkolojisi Kongresi, 2014, ss.170, (Özet Bildiri)

2014

Platin dirençli nüks eden baş boyun tümörlerinde setuximabın rolü, olgu değerlendirmesi

Karabulut S., Ekenel M., Tambaş M., Taştekin D., Altun M., Meral R., Başaran M., Bavbek S.

Türik Tıbbi Onkoloji Kongresi, 2014, ss.363, (Tam Metin Bildiri)

2013

The effects of variability of mean erythrocyte corpuscular volume (MCV) in patients with advanced stage gastrointestinal stromal tumor (GIST) using imatinib on progression free survival

Cetin B., TAŞTEKİN D., Aktas B., Guler T., Kaplan M. A., Berk V., Gumusay O., Dane F., Ozkan M., Benekli M.

European Cancer Congress 2013, cilt.49, (Özet Bildiri)

2013

Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

Ciftci R., Karabulut S., Tastekin D., Sen F., Kilic L., Yildiz I., Keskin S., Tas F.

European Cancer Congress 2013, cilt.49, (Özet Bildiri)

2013

Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness

Karabulut S., Kilic L., Ciftci R., Yildiz I., Sen F., Keskin S., Tastekin D., Tas F.

49th Annual Meeting of ASCO, 2013, cilt.31, (Özet Bildiri)

2013

Comparison of mucosal and cutaneous melanoma in the head and neck region

Ciftci R., Keskin S., Karabulut S., Yildiz I., Kilic L., Sen F., Tastekin D., Tas F.

49th Annual Meeting of ASCO, 2013, cilt.31, (Özet Bildiri)

2013

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer

Turan N., Dane F., Unal O. U., Benekli M., Kara H. V., Koca D., Balvan O., Eren T., Tastekin D., Dogan E., et al.

49th Annual Meeting of ASCO, 2013, cilt.31, (Özet Bildiri)